about
The role of CD95 and CD95 ligand in cancerTGF-beta: a mobile purveyor of immune privilegeImmunosuppressive strategies that are mediated by tumor cellsTRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroProtEx technology for the generation of novel therapeutic cancer vaccinesClinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.A vision of cell death: Fas ligand and immune privilege 10 years later.Immunodeficiency and immunotherapy in multiple myeloma.Dual role of macrophages in the response of C26 colon carcinoma cells to 5-fluorouracil administration.Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Stimulation of FasL induces production of proinflammatory mediators through activation of mitogen-activated protein kinases and nuclear factor-κB in THP-1 cells.Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis.Posttranslational regulation of Fas ligand function.Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.Cytomegalovirus and tumors: two players for one goal-immune escape.Colon cancer and the immune system: the role of tumor invading T cells.Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers.Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.[The interplay of immunotherapy and chemotherapy, a novel approach].[Dissecting the pathways of tumour escape: " question of life and death?"].Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death.
P2860
Q26995847-EB27F3D0-C669-482D-A78B-A06464D25C49Q28263622-144932E7-3C48-4DC4-8366-CC9331DF2A2DQ29636247-BE82A9CB-4BC4-48B6-9481-6EF4EC8E6015Q33802751-F76A7F78-8C1E-4803-BEA4-8ABB8C886DB3Q34048819-5BAE5FB7-65E8-449E-89C6-583AFBCCEDA4Q34607210-18713099-9604-445A-8200-675323383182Q35799094-E7BA4E8F-8240-41BE-B17D-27CC7B25B6BDQ35847696-3E06E315-1F06-4E52-ADBE-6620EF97579DQ36508891-FDF92B09-0891-4BF6-9BD3-120E038C50A4Q36593770-D597BC3C-6D6B-4215-8026-F268B363A7DBQ36904977-3EDAB3D5-16EC-4619-B7DE-BB042EF5AEE5Q37108231-84241816-7B6F-4EAA-942F-A86F4548DA9FQ37823518-87D59AB5-6B1D-4EA0-A236-3B026102BA23Q38291229-CEB8E91D-1A6A-44F8-BE61-50F7D826725AQ39312652-59432A8F-43E8-47BB-8BCE-2A5B07971DE8Q39620643-59B1DB00-854A-48B3-A214-56F78C4714CEQ39831618-97F5D4A6-CC97-4865-8A3F-156E5E0ACD75Q40014685-43986CC2-3DDB-4672-B0AC-C3F241D2C84CQ40015586-24FF2462-D944-48A1-B09E-B30F09241063Q41114891-5BB0936E-F5DF-4ABA-BE9B-370E7F276728Q42144694-0AFC3A32-7CA9-48A5-9580-A37F56C35EA6Q42725940-6CC713D3-7495-46E7-B0A2-FFEAE0F20E98Q45512143-922A0B36-70D0-42E8-8776-BDC92A3F5418Q47353687-D915409D-CA99-454F-AF71-9EF6291E4534Q47892317-A7BE0323-6D70-4743-98DF-C4BDA04F47F8Q48144190-7E244FB8-DBCC-4DCE-9F25-98DCD2C77FA7Q48799977-9903A856-8152-40D0-8140-C125AF646955Q53109087-F3D65795-9110-429C-8DB1-1211F6EB19EBQ53320503-08DFBBCF-2858-4F9F-BCD1-00C5FA58A8D7Q53344642-BEC67276-C7CC-4A2A-862A-32D6E51F9801Q53572097-E392F707-D126-446B-AB14-B937DD2C178A
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tumor counterattack: fact or fiction?
@ast
Tumor counterattack: fact or fiction?
@en
Tumor counterattack: fact or fiction?
@nl
type
label
Tumor counterattack: fact or fiction?
@ast
Tumor counterattack: fact or fiction?
@en
Tumor counterattack: fact or fiction?
@nl
prefLabel
Tumor counterattack: fact or fiction?
@ast
Tumor counterattack: fact or fiction?
@en
Tumor counterattack: fact or fiction?
@nl
P1476
Tumor counterattack: fact or fiction?
@en
P2093
Frederik H Igney
Peter H Krammer
P2888
P304
P356
10.1007/S00262-005-0680-7
P577
2005-05-12T00:00:00Z
P6179
1015327619